Reviewing CV Sciences (OTCMKTS:CVSI) and Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) and CV Sciences (OTCMKTS:CVSI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Profitability

This table compares Corcept Therapeutics and CV Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	14.19%	15.99%	12.70%
CV Sciences	-10.29%	-84.11%	-19.30%

Insider and Institutional Ownership

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by insiders. Comparatively, 3.8% of CV Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Corcept Therapeutics and CV Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$741.17 million	4.93	$141.21 million	$0.88	39.47
CV Sciences	$15.70 million	0.55	-$2.39 million	N/A	N/A

Corcept Therapeutics has higher revenue and earnings than CV Sciences.

Risk and Volatility

Corcept Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, CV Sciences has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Corcept Therapeutics and CV Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	2	2	4	0	2.25
CV Sciences	0	0	0	0	0.00

Corcept Therapeutics presently has a consensus target price of $80.83, indicating a potential upside of 132.75%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Corcept Therapeutics is more favorable than CV Sciences.

Summary

Corcept Therapeutics beats CV Sciences on 11 of the 12 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About CV Sciences

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.